BR0209161A - Composição de vacina, kit de vacinação, método de tratamento médico, uso de um antìgeno de hpv, e, métodos para preparar uma vacina e para diminuir a transmissão viral do hiv - Google Patents

Composição de vacina, kit de vacinação, método de tratamento médico, uso de um antìgeno de hpv, e, métodos para preparar uma vacina e para diminuir a transmissão viral do hiv

Info

Publication number
BR0209161A
BR0209161A BR0209161A BR0209161A BR0209161A BR 0209161 A BR0209161 A BR 0209161A BR 0209161 A BR0209161 A BR 0209161A BR 0209161 A BR0209161 A BR 0209161A BR 0209161 A BR0209161 A BR 0209161A
Authority
BR
Brazil
Prior art keywords
vaccine
preparing
methods
treatment method
medical treatment
Prior art date
Application number
BR0209161A
Other languages
English (en)
Inventor
Serge Debrus
Nathalie Louise Mathy
Gerald Voss
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BR0209161A publication Critical patent/BR0209161A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO DE VACINA, KIT DE VACINAçãO, MéTODO DE TRATAMENTO MéDICO, USO DE UM ANTìGENO DE HPV, E, MéTODOS PARA PREPARAR UMA VACINA E PARA DIMINUIR A TRANSMISSãO VIRAL DO HIV". A presente invenção diz respeito a uma composição de vacina que compreende pelo menos um antígeno do vírus da imunodeficiência humana (HIV) e um ou ambos de: i) pelo menos um antígeno do vírus do herpes simplex (HSV) e ii) pelo menos um antígeno do papilomavírus humano (HPV).
BR0209161A 2001-04-27 2002-04-25 Composição de vacina, kit de vacinação, método de tratamento médico, uso de um antìgeno de hpv, e, métodos para preparar uma vacina e para diminuir a transmissão viral do hiv BR0209161A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0110431A GB0110431D0 (en) 2001-04-27 2001-04-27 Novel compounds
PCT/EP2002/004966 WO2002087614A2 (en) 2001-04-27 2002-04-25 Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen

Publications (1)

Publication Number Publication Date
BR0209161A true BR0209161A (pt) 2004-08-03

Family

ID=9913641

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209161A BR0209161A (pt) 2001-04-27 2002-04-25 Composição de vacina, kit de vacinação, método de tratamento médico, uso de um antìgeno de hpv, e, métodos para preparar uma vacina e para diminuir a transmissão viral do hiv

Country Status (20)

Country Link
US (1) US20040131638A1 (pt)
EP (1) EP1381390A2 (pt)
JP (1) JP2004531540A (pt)
KR (1) KR20040030599A (pt)
CN (1) CN1522153A (pt)
AR (1) AR034312A1 (pt)
AU (1) AU2002310802B2 (pt)
BR (1) BR0209161A (pt)
CA (1) CA2445310A1 (pt)
CZ (1) CZ20032942A3 (pt)
GB (1) GB0110431D0 (pt)
HU (1) HUP0303942A3 (pt)
IL (1) IL158428A0 (pt)
MX (1) MXPA03009698A (pt)
MY (1) MY134041A (pt)
NO (1) NO20034695L (pt)
NZ (1) NZ529039A (pt)
PL (1) PL367134A1 (pt)
WO (1) WO2002087614A2 (pt)
ZA (1) ZA200308188B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
US8778351B2 (en) * 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
JP5639361B2 (ja) 2006-09-08 2014-12-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｓｖ−１及びｈｓｖ−２ワクチン並びにその使用方法
US8865185B2 (en) 2006-09-08 2014-10-21 The Trustees Of The University Of Pennsylvania Methods of use for HSV-1 and HSV-2 vaccines
US10478490B2 (en) 2006-12-28 2019-11-19 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2008085486A1 (en) * 2006-12-28 2008-07-17 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
US8057804B2 (en) 2006-12-28 2011-11-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
ES2565846T3 (es) * 2008-05-26 2016-04-07 Cadila Healthcare Limited Vacuna combinada contra el sarampión-papiloma humano
WO2010074126A1 (ja) * 2008-12-25 2010-07-01 財団法人化学及血清療法研究所 組換え鶏伝染性コリーザワクチン及びその製造方法
EP2746394A4 (en) * 2011-08-19 2015-07-15 Ostrich Pharma Kk ANTIBODY AND COMPOSITION CONTAINING THE SAME
EP3209676A4 (en) * 2014-10-24 2018-03-28 Hpvvax, Llc Cancer and skin lesion treatment
BR112018067550A2 (pt) * 2016-02-27 2019-10-01 Hpvvax Llc métodos para tratar um paciente que tem câncer de pele, tumor benigno ou canceroso ou uma lesão associada a papilomavírus humano (hpv), e composição farmacêutica
PE20191547A1 (es) 2016-12-26 2019-10-24 Mogam Inst Biomedical Res Composicion de vacuna contra el herpes zoster

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9620795D0 (en) * 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ATE454901T1 (de) * 1999-10-13 2010-01-15 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen

Also Published As

Publication number Publication date
HUP0303942A2 (hu) 2004-03-01
GB0110431D0 (en) 2001-06-20
HUP0303942A3 (en) 2005-11-28
IL158428A0 (en) 2004-05-12
WO2002087614A3 (en) 2003-04-24
CN1522153A (zh) 2004-08-18
JP2004531540A (ja) 2004-10-14
CZ20032942A3 (cs) 2004-12-15
AU2002310802B2 (en) 2005-03-24
ZA200308188B (en) 2005-01-21
NZ529039A (en) 2005-02-25
NO20034695L (no) 2003-12-03
EP1381390A2 (en) 2004-01-21
KR20040030599A (ko) 2004-04-09
AR034312A1 (es) 2004-02-18
PL367134A1 (en) 2005-02-21
WO2002087614A2 (en) 2002-11-07
US20040131638A1 (en) 2004-07-08
MXPA03009698A (es) 2004-01-29
NO20034695D0 (no) 2003-10-20
MY134041A (en) 2007-11-30
CA2445310A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
BR0209161A (pt) Composição de vacina, kit de vacinação, método de tratamento médico, uso de um antìgeno de hpv, e, métodos para preparar uma vacina e para diminuir a transmissão viral do hiv
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
WO1999033868A3 (en) Human papillomavirus vaccine
HUP0301308A2 (hu) Emberi Papillomavírus-fertőzés gyógykezelése
BR9814606A (pt) Formulação de vacina e métodos de tratamento de um indivìduo infectado com um vìrus hpv e de prevenção de infecção por papiloma vìrus
DE60110822D1 (de) Zubereitung zur immunisierung gegen den aids-virus
BR0114786A (pt) Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
BR9908599A (pt) Composições combinadas de vacina
EP1246644A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMA VIRUS USING PEPTIDES AND NUCLEIC ACID COMPOSITIONS
WO1999010375A3 (en) Vaccine against hpv
BR0308444A (pt) Composição de vacina, método de produção de vacina, uso de uma mistura de vlps de hpv 16, hpv 18, hvp 31 e hpv 45, método de prevenção da infecção por hpv ou tratamento de doença relacionada com a infecção por hpv
BR0317544A (pt) Uso de uma composição que compreende vlps de hpv 16 e hpv 18, e, métodos para induzir uma resposta imune contra um ou mais do grupo de tipos de hpv oncogênicos, para prevenir infecção e/ou doença causada por um ou mais do grupo de tipos de hpv oncogênicos, para prevenir a infecção de uma população de pacientes por um ou mais tipos de hpv, uso de uma mistura de vlps de hpv 16 e hpv18, e, composição de vacina
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
DE69131200T2 (de) Herpes simplex virus vp16 impfstoffe
DK1531843T3 (da) Fremgangsmåde til behandling af cervixcancer
WO2003078640A3 (en) Recombinant drug-sensitive vaccinia virus as smallpox vaccine
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
AR002758A1 (es) Oligonucleotidos especificos para virus de papiloma humano, composicion farmaceutica que los contiene, el uso de los oligonucleotidos, un kit para ladeteccion y el metodo para dicha deteccion.
BR0012985A (pt) Vacina, bactéria, uso da mesma, e composição farmacêutica e métodos de tratamento ou prevenção de doença mediada por hsv em um hospedeiro humano ou animal e de uma infecção viral da mucosa de um hospedeiro humano ou animal
DK56389D0 (da) Forhindring og behandling af retroviralt frembragte sygdomme
ATE478679T1 (de) Verfahren zur anwendung von ionisierungsstrahlung bei einer hiv-infektionstherapie
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
WO2002070004A3 (en) Papillomavirus vaccines
BR0211181A (pt) Formulação vacinal
DK0929315T3 (da) Krydsbeskyttende equine herpesviruspræparater, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.